Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label study designed to evaluate the long-term safety and efficacy of
evinacumab, a fully human ANGPTL3 antibody, in patients with homozygous familial
hypercholesterolemia (HoFH), in a real-life setting in Canada.
Eligible patients for this study are male and female adult patients with HoFH. Evinacumab
will be added on top of the patient's background lipid-modifying therapy (LMT), including
statins, ezetimibe, PCSK9 inhibitors, lomitapide or other lipid lowering therapies. This
study will be conducted using an hybrid (on-site, foldable sites) approach. Patients will
enter the current study, in an open-label treatment period, following their screening. This
study will continue until reimbursement of evinacumab in Canada or for a maximum of 24
months. The end of study (EoS) visit will be scheduled 4 weeks after the last dose has been
injected and will be followed by a 52-week follow-up.